查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1716422

2032 年病毒抗原市場預測：按類型、病毒類型、通路、診斷方法、應用、最終用戶和地區進行的全球分析

Viral Antigens Market Forecasts to 2032 - Global Analysis By Type, Virus Type, Distribution Channel, Diagnostic Method, Application, End Users and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球病毒抗原市場預計在 2025 年達到 2,354 億美元，預計到 2032 年將達到 4,646 億美元，預測期內的複合年成長率為 10.2%。

病毒抗原是源自病毒的分子，可引發人體的免疫反應。這些抗原通常是病毒表面的蛋白質或糖蛋白，被免疫系統識別為外來物質並刺激抗體的產生。病毒抗原在診斷測試、疫苗開發和研究中發揮重要作用。這是因為它可以幫助檢測病毒感染、刺激免疫力並了解病毒行為及其與免疫系統的相互作用。

根據美國國家生物技術資訊中心 (NCBI) 的數據，64.44% 的病毒特異性B 細胞表位位於病毒抗原上，這些抗原仍被包裹在病毒顆粒或宿主細胞內。

病毒感染增加

隨著世界各地出現新的病毒，對準確診斷和有效抗原治療的需求日益增加。 COVID-19、肝炎和流感等病毒性疾病凸顯了基於抗原的診斷的重要性。通用感染疾病發生率的上升進一步凸顯了研究和開發病毒抗原的必要性。此外，技術突破使得人們能夠開發出更強大的抗原來對抗病毒感染疾病。總的來說，這些因素導致全球對病毒抗原的需求不斷增加。

抗原生產高成本

抗原生產過程涉及重組DNA和單株抗體等昂貴的技術。此外，對專門設施和熟練專業人員的需求也增加了生產成本。品管和安全測試的監管要求進一步增加了製造商的成本。這些成本使得抗原生產對於小公司和開發中國家來說在經濟上具有挑戰性。這種限制阻礙了病毒抗原在不同地區的廣泛可用性和可負擔性。

對預防性醫療保健的興趣日益濃厚

世界各國政府和組織都重視疫苗接種計劃，以遏制病毒感染疾病的傳播。基於抗原的疫苗在實現預防保健目標中發揮著重要作用。此外，免疫學和抗原技術的進步正在推動疫苗開發的創新。公眾對定期檢查和接種疫苗等預防措施的認知正在推動市場需求。這一趨勢為公司擴大抗原產品組合和滿足全球醫療保健需求提供了巨大潛力。

某些病毒抗原的可用性有限

由於病毒結構複雜，有些抗原難以取得或產生。這種限制影響了新發病毒診斷測試和疫苗的及時開發。例如，罕見病毒株或快速變異的病毒可能缺乏適合研究的抗原。此外，供應鏈中斷和地緣政治因素可能會影響某些地區的抗原供應。這些問題威脅到製造商滿足日益成長的病毒抗原需求的能力。

COVID-19的影響：

COVID-19 疫情對病毒抗原市場產生了重大影響。基於抗原的病毒診斷檢測方法的開發和採用已經加速。對 COVID-19 疫苗的高需求進一步凸顯了病毒抗原的重要性。疫情爆發後，人們依然高度重視醫療準備和疫苗研發。這場大流行凸顯了病毒抗原在應對全球健康挑戰中的作用，推動了市場成長。

預計預測期內，天然抗原部分將佔最大佔有率

由於天然抗原的組成與病毒的結構非常相似並提供精確的免疫反應，因此預計天然抗原部分將在預測期內佔據最大的市場佔有率。它們在診斷和疫苗開發中的應用對於檢測感染和刺激有效免疫至關重要。此外，天然抗原由於其能夠產生強大而持久的免疫力而成為疫苗製劑的首選，這增加了其在研究、診斷和治療應用中的需求。

預計治療應用領域在預測期內將以最高複合年成長率成長

由於治療應用領域具有增強免疫療法和抗病毒治療的潛力，預計在預測期內將出現最高的成長率。透過刺激有針對性的免疫反應，病毒抗原可能有助於治療慢性病毒感染和增強人體的防禦機制。人們對個人化醫療和病毒性疾病新型治療方法的日益關注將進一步推動對用於治療的病毒抗原的需求，以改善患者的治療效果。

佔比最大的地區：

由於肝炎、流感和 COVID-19 等病毒感染疾病的盛行率不斷上升，預計亞太地區將在預測期內佔據最大的市場佔有率。快速的都市化、改善的醫療保健基礎設施以及對研究和診斷的不斷增加的投資進一步推動了市場的成長。此外，政府努力加強疫苗接種計劃和診斷檢測，以及提高對病毒性疾病的認知，大大推動了全部區域對病毒抗原的需求。

複合年成長率最高的地區：

由於流感、愛滋病毒和 COVID-19 等病毒感染疾病的盛行率很高，預計歐洲地區在預測期內的複合年成長率最高，增加了對診斷測試和疫苗的需求。先進的醫療基礎設施、廣泛的生物技術研發以及政府對公共衛生舉措的大力支持促進了市場的成長。此外，對病毒性疾病的認知不斷提高以及快速診斷的需求是推動該地區對病毒抗原需求的主要因素。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球病毒抗原市場（按類型）

  • 天然抗原
  • 重組抗原
  • 合成抗原
  • 去活化抗原
  • 減毒活抗原
  • 其他類型

6. 全球病毒抗原市場（依病毒類型）

  • 人類免疫力缺乏病毒（HIV）
  • 流感病毒
  • 肝炎病毒
  • COVID-19（SARS-CoV-2）
  • 單純皰疹病毒（HSV）
  • 其他病毒類型

7. 全球病毒抗原市場（依通路）

  • 直銷
  • 網上銷售
  • 第三方經銷商
  • 零售藥局

8. 全球病毒抗原市場（依診斷方法）

  • 基於抗原的診斷套件
  • 免疫過氧化物酶染色
  • 免疫檢測
  • 血凝反應
  • 免疫測量（RIA）
  • 螢光
  • 電子顯微鏡

9. 全球病毒抗原市場（依應用）

  • 診斷
    • 病毒檢測測試
    • 血清學檢測
    • 聚合酵素鏈鎖反應反應（PCR）
  • 疫苗研發
  • 研究與開發
  • 治療用途
  • 其他用途

第 10 章全球病毒抗原市場（依最終用戶）

  • 研究和診斷實驗室
  • 製藥和生物技術公司
  • 醫院
  • 學術和政府研究組織
  • 獸醫診所
  • 其他最終用戶

第 11 章全球病毒抗原市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • Creative Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Microbix Biosystems Inc.
  • Aalto Bio Reagents
  • Prospec-Tany Technogene Ltd.
  • Sino Biological, Inc.
  • Meridian Bioscience
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • Abbott
  • Cepheid
  • The Native Antigen Company
  • DiaSorin SpA
  • Quidel Corporation
  • Randox Laboratories Ltd.
Product Code: SMRC29233

According to Stratistics MRC, the Global Viral Antigens Market is accounted for $235.40 billion in 2025 and is expected to reach $464.60 billion by 2032 growing at a CAGR of 10.2% during the forecast period. Viral antigens are molecules derived from viruses that trigger an immune response in the body. These antigens, typically proteins or glycoproteins found on the surface of the virus, are recognized by the immune system as foreign, prompting the production of antibodies. Viral antigens play a crucial role in diagnostic tests, vaccine development, and research, as they help detect viral infections, stimulate immunity, and contribute to understanding viral behaviors and interactions with the immune system.

According to the National Centre for Biotechnology Information (NCBI), 64.44% virus-specific B cell epitopes are situated in viral antigens that remain enclosed within viral particles or host cells.

Market Dynamics:

Driver:

Increasing prevalence of viral infections

The demand for precise diagnoses and efficient antigen-based treatments is increasing as novel strains appear all over the world. The significance of antigen-based diagnostics has been brought to light by viral illnesses such as COVID-19, hepatitis, and influenza. The need for viral antigen research and development is further highlighted by the rising incidence of zoonotic illnesses. Furthermore, the development of more potent antigens to fight viral outbreaks has been made possible by technological breakthroughs. These factors collectively contribute to the increased demand for viral antigens worldwide.

Restraint:

High costs of antigen production

The manufacturing process for antigens involves expensive technologies like recombinant DNA and monoclonal antibodies. Additionally, the need for specialized facilities and skilled professionals adds to the production cost. Regulatory requirements for quality control and safety testing further increase expenses for manufacturers. Small-scale companies and developing nations face financial challenges in antigen production due to these costs. This limitation hampers widespread accessibility and affordability of viral antigens across various regions.

Opportunity:

Growing focus on preventive healthcare

Governments and organizations worldwide are emphasizing vaccination programs to curb the spread of viral infections. Antigen-based vaccines play a crucial role in achieving preventive healthcare objectives. Moreover, advancements in immunology and antigen technologies are driving innovation in vaccine development. Public awareness about preventive measures, such as regular screening and vaccination, is boosting market demand. This trend creates immense potential for companies to expand their antigen product portfolios and cater to global healthcare needs.

Threat:

Limited Availability of Certain Viral Antigens

Some antigens are difficult to source or produce due to the complexity of viral structures. This limitation affects the timely development of diagnostic tests and vaccines for emerging viruses. For instance, rare viral strains or rapidly mutating viruses may lack suitable antigens for research. Additionally, supply chain disruptions and geopolitical factors can affect antigen availability in certain regions. These issues threaten the ability of manufacturers to meet the growing demand for viral antigens.

Covid-19 Impact:

The COVID-19 pandemic has had a profound impact on the Viral Antigens Market. It accelerated the development and adoption of antigen-based diagnostic tests to detect the virus. The high demand for COVID-19 vaccines further highlighted the importance of viral antigens. Post-pandemic, the focus on healthcare preparedness and vaccine development remains strong. The pandemic emphasized the role of viral antigens in addressing global health challenges and driving market growth.

The native antigens segment is expected to be the largest during the forecast period

The native antigens segment is expected to account for the largest market share during the forecast period, due to their natural composition, which closely mimics the structure of the virus, providing accurate immune responses. Their use in diagnostics and vaccine development is crucial for detecting infections and stimulating effective immunity. Additionally, native antigens are preferred in vaccine formulations for their ability to produce robust and long-lasting immunity, increasing demand across research, diagnostics, and therapeutic applications.

The therapeutic use segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the therapeutic use segment is predicted to witness the highest growth rate, driven by their potential to enhance immunotherapies and antiviral treatments. By stimulating targeted immune responses, viral antigens can aid in treating chronic viral infections or boosting the body's defense mechanisms. The increasing focus on personalized medicine and the development of novel treatments for viral diseases further propels the demand for viral antigens in therapeutic applications, improving patient outcomes.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to the increasing prevalence of viral infections, such as hepatitis, influenza, and COVID-19. Rapid urbanization, improving healthcare infrastructure, and growing investments in research and diagnostics are further fueling market growth. Additionally, government initiatives promoting vaccination programs and diagnostic testing, along with the rising awareness of viral diseases, are significantly boosting the demand for viral antigens across the region.

Region with highest CAGR:

Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR, owing to the high prevalence of viral infections, including influenza, HIV, and COVID-19, which increases the demand for diagnostic tests and vaccines. Advanced healthcare infrastructure, extensive research and development in biotechnology, and strong government support for public health initiatives contribute to market growth. Furthermore, rising awareness of viral diseases and the need for rapid diagnostics are key factors driving demand for viral antigens in the region.

Key players in the market

Some of the key players in Viral Antigens Market include Creative Diagnostics, Bio-Rad Laboratories, Inc., Microbix Biosystems Inc., Aalto Bio Reagents, Prospec-Tany Technogene Ltd., Sino Biological, Inc., Meridian Bioscience, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Abbott, Cepheid, The Native Antigen Company, DiaSorin S.p.A, Quidel Corporation, and Randox Laboratories Ltd.

Key Developments:

In February 2025, Shedd Aquarium and global healthcare company Abbott are announcing one of Shedd's largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.

In November 2024, Microbix Biosystems Inc. announces that key opinion leader ("KOL") collaborators are presenting results of a Microbix Quality Assessment Product ("QAP(TM)") for controlling testing for high-risk types of Human Papilloma Virus ("HPV") at the 36th annual International Papillomavirus Conference ("IPVC") taking place in Edinburgh, Scotland.

Types Covered:

  • Native Antigens
  • Recombinant Antigens
  • Synthetic Antigens
  • Inactivated Antigen
  • Live Attenuated Antigens
  • Other Types

Virus Types Covered:

  • Human Immunodeficiency Virus (HIV)
  • Influenza Virus
  • Hepatitis Virus
  • COVID-19 (SARS-CoV-2)
  • Herpes Simplex Virus (HSV)
  • Other Virus Types

Distribution Channels Covered:

  • Direct Sales
  • Online Sales
  • Third-Party Distributors
  • Retail Pharmacies

Diagnostic Methods Covered:

  • Antigen-based Diagnostic Kits
  • Immunoperoxidase Staining
  • Immunoassays
  • Hemagglutination
  • Radioimmunoassay (RIA)
  • Immunofluorescence
  • Electron Microscopy

Applications Covered:

  • Diagnostics
  • Vaccine Development
  • Research and Development
  • Therapeutic Use
  • Other Applications

End Users Covered:

  • Research and Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Hospitals
  • Academic and Government Research Institutes
  • Veterinary Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Viral Antigens Market, By Type

  • 5.1 Introduction
  • 5.2 Native Antigens
  • 5.3 Recombinant Antigens
  • 5.4 Synthetic Antigens
  • 5.5 Inactivated Antigen
  • 5.6 Live Attenuated Antigens
  • 5.7 Other Types

6 Global Viral Antigens Market, By Virus Type

  • 6.1 Introduction
  • 6.2 Human Immunodeficiency Virus (HIV)
  • 6.3 Influenza Virus
  • 6.4 Hepatitis Virus
  • 6.5 COVID-19 (SARS-CoV-2)
  • 6.6 Herpes Simplex Virus (HSV)
  • 6.7 Other Virus Types

7 Global Viral Antigens Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct Sales
  • 7.3 Online Sales
  • 7.4 Third-Party Distributors
  • 7.5 Retail Pharmacies

8 Global Viral Antigens Market, By Diagnostic Method

  • 8.1 Introduction
  • 8.2 Antigen-based Diagnostic Kits
  • 8.3 Immunoperoxidase Staining
  • 8.4 Immunoassays
  • 8.5 Hemagglutination
  • 8.6 Radioimmunoassay (RIA)
  • 8.7 Immunofluorescence
  • 8.8 Electron Microscopy

9 Global Viral Antigens Market, By Application

  • 9.1 Introduction
  • 9.2 Diagnostics
    • 9.2.1 Viral Detection Tests
    • 9.2.2 Serology Tests
    • 9.2.3 Polymerase Chain Reaction Assays (PCR)
  • 9.3 Vaccine Development
  • 9.4 Research and Development
  • 9.5 Therapeutic Use
  • 9.6 Other Applications

10 Global Viral Antigens Market, By End User

  • 10.1 Introduction
  • 10.2 Research and Diagnostic Laboratories
  • 10.3 Pharmaceutical and Biotechnology Companies
  • 10.4 Hospitals
  • 10.5 Academic and Government Research Institutes
  • 10.6 Veterinary Clinics
  • 10.7 Other End Users

11 Global Viral Antigens Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Creative Diagnostics
  • 13.2 Bio-Rad Laboratories, Inc.
  • 13.3 Microbix Biosystems Inc.
  • 13.4 Aalto Bio Reagents
  • 13.5 Prospec-Tany Technogene Ltd.
  • 13.6 Sino Biological, Inc.
  • 13.7 Meridian Bioscience
  • 13.8 F. Hoffmann-La Roche Ltd
  • 13.9 Thermo Fisher Scientific, Inc.
  • 13.10 Abbott
  • 13.11 Cepheid
  • 13.12 The Native Antigen Company
  • 13.13 DiaSorin S.p.A
  • 13.14 Quidel Corporation
  • 13.15 Randox Laboratories Ltd.

List of Tables

  • Table 1 Global Viral Antigens Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Viral Antigens Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Viral Antigens Market Outlook, By Native Antigens (2024-2032) ($MN)
  • Table 4 Global Viral Antigens Market Outlook, By Recombinant Antigens (2024-2032) ($MN)
  • Table 5 Global Viral Antigens Market Outlook, By Synthetic Antigens (2024-2032) ($MN)
  • Table 6 Global Viral Antigens Market Outlook, By Inactivated Antigen (2024-2032) ($MN)
  • Table 7 Global Viral Antigens Market Outlook, By Live Attenuated Antigens (2024-2032) ($MN)
  • Table 8 Global Viral Antigens Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 9 Global Viral Antigens Market Outlook, By Virus Type (2024-2032) ($MN)
  • Table 10 Global Viral Antigens Market Outlook, By Human Immunodeficiency Virus (HIV) (2024-2032) ($MN)
  • Table 11 Global Viral Antigens Market Outlook, By Influenza Virus (2024-2032) ($MN)
  • Table 12 Global Viral Antigens Market Outlook, By Hepatitis Virus (2024-2032) ($MN)
  • Table 13 Global Viral Antigens Market Outlook, By COVID-19 (SARS-CoV-2) (2024-2032) ($MN)
  • Table 14 Global Viral Antigens Market Outlook, By Herpes Simplex Virus (HSV) (2024-2032) ($MN)
  • Table 15 Global Viral Antigens Market Outlook, By Other Virus Types (2024-2032) ($MN)
  • Table 16 Global Viral Antigens Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 17 Global Viral Antigens Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 18 Global Viral Antigens Market Outlook, By Online Sales (2024-2032) ($MN)
  • Table 19 Global Viral Antigens Market Outlook, By Third-Party Distributors (2024-2032) ($MN)
  • Table 20 Global Viral Antigens Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 21 Global Viral Antigens Market Outlook, By Diagnostic Method (2024-2032) ($MN)
  • Table 22 Global Viral Antigens Market Outlook, By Antigen-based Diagnostic Kits (2024-2032) ($MN)
  • Table 23 Global Viral Antigens Market Outlook, By Immunoperoxidase Staining (2024-2032) ($MN)
  • Table 24 Global Viral Antigens Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 25 Global Viral Antigens Market Outlook, By Hemagglutination (2024-2032) ($MN)
  • Table 26 Global Viral Antigens Market Outlook, By Radioimmunoassay (RIA) (2024-2032) ($MN)
  • Table 27 Global Viral Antigens Market Outlook, By Immunofluorescence (2024-2032) ($MN)
  • Table 28 Global Viral Antigens Market Outlook, By Electron Microscopy (2024-2032) ($MN)
  • Table 29 Global Viral Antigens Market Outlook, By Application (2024-2032) ($MN)
  • Table 30 Global Viral Antigens Market Outlook, By Diagnostics (2024-2032) ($MN)
  • Table 31 Global Viral Antigens Market Outlook, By Viral Detection Tests (2024-2032) ($MN)
  • Table 32 Global Viral Antigens Market Outlook, By Serology Tests (2024-2032) ($MN)
  • Table 33 Global Viral Antigens Market Outlook, By Polymerase Chain Reaction Assays (PCR) (2024-2032) ($MN)
  • Table 34 Global Viral Antigens Market Outlook, By Vaccine Development (2024-2032) ($MN)
  • Table 35 Global Viral Antigens Market Outlook, By Research and Development (2024-2032) ($MN)
  • Table 36 Global Viral Antigens Market Outlook, By Therapeutic Use (2024-2032) ($MN)
  • Table 37 Global Viral Antigens Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 38 Global Viral Antigens Market Outlook, By End User (2024-2032) ($MN)
  • Table 39 Global Viral Antigens Market Outlook, By Research and Diagnostic Laboratories (2024-2032) ($MN)
  • Table 40 Global Viral Antigens Market Outlook, By Pharmaceutical and Biotechnology Companies (2024-2032) ($MN)
  • Table 41 Global Viral Antigens Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 42 Global Viral Antigens Market Outlook, By Academic and Government Research Institutes (2024-2032) ($MN)
  • Table 43 Global Viral Antigens Market Outlook, By Veterinary Clinics (2024-2032) ($MN)
  • Table 44 Global Viral Antigens Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.